M.B.B.S

Recor Medical Announces U.S. Launch and First Commercial Cases of Paradise Ultrasound Renal Denervation Therapy

Retrieved on: 
Friday, November 10, 2023
Health, Medical Devices, General Health, Radiology, Clinical Trials, Cardiology, Biotechnology, Medicine, Arm, Food and Drug Administration, Disease, DRS, Hypertension, Food, M.B.B.S, RDN, Physician, Structural heart disease, Surgeon, Mortality, Cardiovascular disease, TRIO, Cleveland Clinic, Multimedia, Patient, Renal artery, Kaleida Health, Division, FDA, Master of Science, Gates Vascular Institute, Intervention, Biomedical sciences, University, MD, Doctor of Philosophy, Hospital, NewYork-Presbyterian Hospital, Blood pressure, Medical imaging, Pharmaceutical industry, Buffalo, Paradise

Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced the first commercial uses of Recor’s Paradise™ Ultrasound Renal Denervation (uRDN) system for the treatment of hypertension, the first FDA approved renal denervation therapy in the United States.

Key Points: 
  • Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced the first commercial uses of Recor’s Paradise™ Ultrasound Renal Denervation (uRDN) system for the treatment of hypertension, the first FDA approved renal denervation therapy in the United States.
  • The first commercial procedures took place at NewYork-Presbyterian/Columbia University Irving Medical Center in New York City by Drs.
  • Paradise uRDN delivers two to three doses of 360-degree ultrasound energy — lasting seven seconds each — through the main renal arteries to the surrounding nerves.
  • “This new renal denervation technology for a high-risk patient population – individuals with difficult to control hypertension – has been long awaited.

Verily launches Viewpoint Workbench to unify data and accelerate biomedical research

Retrieved on: 
Thursday, October 5, 2023
Research, Networks, Pharmaceutical, Data Management, Technology, Genetics, Health Technology, Clinical Trials, Science, Biotechnology, Other Science, Health, Parkinson's disease, ALS, The Michael J. Fox Foundation, Biomedical Research, Drug development, GP2, Organization, Data, Disease, AMP, Collection, Ecosystem, Environment, MJFF, Policy, Bangladesh Technical Education Board, Drug discovery, Genomics, ASAP, Medical device, Pharmaceutical industry, Helix, Workbench, M.B.B.S

Verily, an Alphabet precision health technology company, has launched Viewpoint Workbench, a new enterprise-grade platform to unify multimodal data and accelerate biomedical research.

Key Points: 
  • Verily, an Alphabet precision health technology company, has launched Viewpoint Workbench, a new enterprise-grade platform to unify multimodal data and accelerate biomedical research.
  • Workbench provides a secure collaborative environment for data generators, research, and biopharma organizations to govern and analyze their data.
  • Data generating organizations, research sponsors, and biomedical researchers can use Workbench to securely connect with stakeholders and partners, explore and analyze multimodal data, and simplify data governance with access control and policy enforcement.
  • Workbench users can tap into a growing ecosystem of data sources and researchers, to build on collective scientific progress, share best practices, and conduct reproducible research.

Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis

Retrieved on: 
Monday, June 5, 2023
Inflammation, KOL, Expanded access, Coronavirus Scientific Advisory Board, PET, Brain, Research, Multiple sclerosis, Harvard University, Assistant, MS, Harvard Medical School, Nerve, Nuclear medicine, Patient, Mass, Access, Neurology, DSM-IV codes, Microglia, Hospital, HMS, FDA, Positron emission tomography, ALS, Pharmaceutical industry, Medical imaging, Brigham, M.B.B.S, SPMS

Activated microglia are believed to play a prominent role in the pathogenesis of neuroinflammatory diseases including multiple sclerosis, Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).

Key Points: 
  • Activated microglia are believed to play a prominent role in the pathogenesis of neuroinflammatory diseases including multiple sclerosis, Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).
  • A reduction in microglial activation is associated with lowered inflammation in the brain.
  • Inflammation in the brain drives the disease pathology in multiple sclerosis.
  • This finding is even more remarkable because all of the 6 expanded access patients’ na-SPMS had clinically regressed on ocrelizumab treatment.

Obsidian Therapeutics Announces Dr. Madan Jagasia as Chief Executive Officer and Other Leadership Appointments

Retrieved on: 
Tuesday, May 23, 2023
Science, Biometrics, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Vanderbilt-Ingram Cancer Center, Medical Affairs Bureau, University, M.B.B.S, TIL, Hematology, Medical college, Clinical research, Cancer, Vanderbilt University Medical Center, King Edward Memorial Hospital and Seth Gordhandas Sunderdas Medical College, DRS, Medicine, Vanderbilt University, Columbia Business School, Iovance Biotherapeutics, Maryland School, Business administration, Division, Translational research, Transplant, Interventional oncology, University of Maryland School of Medicine, Medical College of Wisconsin, Congress, Master of Business Administration, SomaLogic, Therapy, Society, Nursing, Management, Obsidian

Obsidian Therapeutics Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the appointment of Madan Jagasia, M.D., M.S., as Chief Executive Officer.

Key Points: 
  • Obsidian Therapeutics Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the appointment of Madan Jagasia, M.D., M.S., as Chief Executive Officer.
  • Before Iovance, he was Chief Medical Officer and Executive Medical Director of Cancer Patient Care Center, Vanderbilt-Ingram Cancer Center (VICC), where he co-led Translational Research and Interventional Oncology Research Program at VICC.
  • Dr. Jagasia began his career as a faculty member in the Division of Hematology-Oncology at Vanderbilt University Medical Center.
  • Dr. Norkunas is an experienced biotechnology executive, currently serving as Chief Financial Officer at Generation Bio.

Evelo Biosciences Announces Publication of Scientific Basis for SINTAX Medicines in Frontiers in Immunology

Retrieved on: 
Tuesday, November 15, 2022
Marketing, COVID-19, Growth, TH1, EVS, Science, Inflammation, Allergy, Pangborn Sensory Science Symposium, McInnes, Arthritis, Seminal vesicles, Asthma, Confidentiality, Risk, T helper 17 cell, Research, Failure, Psoriasis, Biology, Atopic dermatitis, Inflammatory bowel disease, Pharmaceutical industry, M.B.B.S, Immunology, Frontiers

Todays publication in Frontiers in Immunology integrates data from our lab and clinical trials, along with the work of others, to describe our latest understanding of the biology of the small intestinal axis, SINTAX.

Key Points: 
  • Todays publication in Frontiers in Immunology integrates data from our lab and clinical trials, along with the work of others, to describe our latest understanding of the biology of the small intestinal axis, SINTAX.
  • We describe the observed ability of SINTAX medicines to harness natural mechanisms in the small intestine to induce regulatory T cells that can resolve inflammation throughout the body.
  • ET, to explain how these scientific advances inform and further support the development of Evelos clinical portfolio.
  • During the event, members of Evelos leadership team including Dr. Bodmer, Andrea Itano, Ph.D., Head of Research, and Duncan McHale, M.B.B.S., Ph.D., Chief Medical Officer, will discuss the scientific basis for SINTAX medicines.

CareCloud Wellness Brings Providers Next Generation Chronic Care Management Services

Retrieved on: 
Monday, August 29, 2022
CareCloud, Patient, Technology, Government, MTBC, Solution, EHR, Internal medicine, CCM, RCM, Practice management, Health information management, Wellness, M.B.B.S, GLOBE, PXM, Health, Adoption, Telehealth, Medicine

SOMERSET, N.J., Aug. 29, 2022 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: MTBC, MTBCO, MTBCP), a leader in healthcare technology solutions for medical practices and health systems nationwide, has begun deploying its new CareCloud Wellness offering for chronic care management (CCM) to a variety of clients. Since the start of Q2 2022, clients in 12 states, including New York, Washington and Florida, and in nine different practice specialties, ranging from internal medicine, endocrinology to behavioral health have signed up for CareCloud Wellness. Clients utilize CareCloud Wellness to provide software-enabled, CCM services to patients through CareCloud’s expanding suite of digital health solutions to help providers enhance patient care and revenue streams.

Key Points: 
  • Clients utilize CareCloud Wellness to provide software-enabled, CCM services to patients through CareClouds expanding suite of digital health solutions to help providers enhance patient care and revenue streams.
  • CareCloud Wellness is a new, elective digital health program that boosts care for high-risk patients with multiple chronic conditions.
  • More than 40,000 providers count on CareCloud to help them improve patient care while reducing administrative burdens and operating costs.
  • Learn more about our products and services including revenue cycle management (RCM), practice management (PM), electronic health records (EHR), business intelligence, telehealth and patient experience management (PXM) at www.carecloud.com .

Imbria Pharmaceuticals Strengthens Executive Leadership Team with New Appointments

Retrieved on: 
Thursday, March 10, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, MSD, University, Heart, General Medical Council, Industry, Komal, BS, Drug development, Medication, Research, Leadership, Diabetes, Specialist, Heart failure, American Society for Pharmacology and Experimental Therapeutics, Columbia Business School, Carroll School of Management, Duke University, MBA, Patient, Mitochondrion, GMC, Cardiology, London Business School, Drug discovery, University of Oxford, Doctor of Philosophy, Therapy, Hugo, Biotechnology, Experiment, Pharmaceutical industry, Boston College, M.B.B.S, Chemistry

We are at a pivotal juncture of our company, and I am pleased to welcome Arash, Hugo and Komal to the team as Imbria continues to gather momentum, said Anne Prener, M.D., Ph.D., president and chief executive officer of Imbria Pharmaceuticals.

Key Points: 
  • We are at a pivotal juncture of our company, and I am pleased to welcome Arash, Hugo and Komal to the team as Imbria continues to gather momentum, said Anne Prener, M.D., Ph.D., president and chief executive officer of Imbria Pharmaceuticals.
  • Dr. Arash Yavari brings over 20 years of broad clinical, scientific and early drug development experience as a physician scientist to Imbria.
  • in Chemistry from the University of Salford and studied Finance at London Business School and Leadership at Duke University.
  • Komal Joshi brings over 20 years of finance leadership and capital markets experience to Imbria.